Portal de Periódicos da CAPES

Prognostic significance of blood markers of inflammation in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty and effects of pexelizumab, a C5 inhibitor: a substudy of the COMMA trial

2005; Oxford University Press; Volume: 26; Issue: 19 Linguagem: Inglês

10.1093/eurheartj/ehi292

1522-9645

Pierre Théroux, Paul W. Armstrong, Kenneth W. Mahaffey, Judith S. Hochman, Kevin J. Malloy, Scott A. Rollins, José Carlos Nicolau, Joël Lavoie, The Minh Luong, J.E.B. Burchenal, Christopher B. Granger,

Signaling Pathways in Disease

Aims Pexelizumab, a monoclonal antibody inhibiting C5, reduced 90 day mortality and shock in the COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial without apparent reductions in infarct size. Inflammation is a critical component of ST-elevation myocardial infarction (STEMI); this substudy examines prognostic values of selected markers and treatment effects.